SB 225002 and the IL-8 Signaling Divide
2026-10-05
SB 225002 offers a receptor-resolved way to examine CXCR2-dependent neutrophil trafficking while avoiding the assumption that every IL-8 response is CXCR2-mediated. In light of 2026 findings linking MRSA extracellular vesicles to CXCR1-centered signaling in oral squamous cell carcinoma, this article examines what selective CXCR2 pharmacology can establish, where its evidence boundaries lie, and how it can inform translational research strategy.
SB 225002 and the IL-8 Signaling Divide
2026-10-04
The latest evidence linking methicillin-resistant Staphylococcus aureus extracellular vesicles to oral squamous cell carcinoma highlights why IL-8 biology must be resolved at the receptor level. This thought-leadership analysis positions SB 225002 as a research tool for distinguishing CXCR2-dependent neutrophil trafficking from CXCR1-centered tumor-cell signaling, while defining the evidence boundaries for translational interpretation.
SEMA3E, β-Catenin, and Beige Adipocyte Thermogenesis
2026-10-03
A 2026 mouse study identifies SEMA3E as a regulator of beige adipocyte differentiation and non-shivering thermogenesis, linking its activity to mitochondrial oxidative phosphorylation and context-dependent Wnt/β-catenin signaling. The findings broaden mechanistic understanding of adipose tissue plasticity while remaining preclinical and specific to murine models.
EAGLE-1: Oral Gepotidacin for Gonorrhoea
2026-10-02
The phase 3 EAGLE-1 trial found that two oral doses of gepotidacin were non-inferior to ceftriaxone plus azithromycin for microbiological clearance of uncomplicated urogenital gonorrhoea. Its main innovation is clinical validation of an oral, first-in-class antibacterial that inhibits bacterial DNA replication, while its population and susceptibility criteria define important limits on wider generalisation.
Netarsudil (AR-13324) ROCK and siRNA Workflow
2026-10-01
Netarsudil (AR-13324) is more than a ROCK pathway probe: it can connect cytoskeletal phenotyping in trabecular meshwork cells with drug-containing nanoparticle and siRNA experiments. This workflow shows how to prepare, screen, interpret, and troubleshoot the compound while separating established findings from practical optimization suggestions.
Deracoxib: From COX-2 Biology to Translation
2026-10-01
A translational guide to using Deracoxib as a selective COX-2 inhibitor across inflammation, canine pain, and cancer biology models—while separating target engagement from exposure-driven cytotoxicity.
INO80 and Postreplicative DNA Damage Bypass
2026-09-30
The reference study identifies the INO80 chromatin remodeller as an active facilitator of postreplicative daughter-strand gap repair, acting downstream of PCNA ubiquitylation. Its findings separate this function from H2A.Z exchange, transcriptional regulation, and double-strand break repair, providing a mechanistic framework for understanding how chromatin positioning governs DNA damage tolerance.
2-Hydroxypropyl-β-cyclodextrin Protocol Guide
2026-09-30
2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide used to improve the aqueous handling of poorly soluble hydrophobic compounds, particularly molecules containing aromatic or phenyl groups. This dossier-based guide supports formulation and biochemical solubility workflows, but the material should not be treated as evidence of therapeutic efficacy, pharmacokinetic benefit, or use outside validated applications.
Myriocin and Spatial Sphingolipid Biology
2026-09-29
Myriocin is a selective serine palmitoyltransferase inhibitor for dissecting sphingolipid metabolism, inflammation, and tumor biology. This article connects product-level pharmacology with spatial multi-omics evidence to improve assay design and interpretation.
AMG 487: CXCR3 Antagonist Assay Guide
2026-09-29
AMG 487 is a potent, selective CXCR3 antagonist for separating receptor-driven migration, calcium signaling, and macrophage-state effects. This workflow-focused guide connects its assay profile with LAMP1-dependent macrophage polarization and highlights formulation, metabolism, and interpretation controls.
SB 225002: CXCR2 Chemotaxis Assay Workflows
2026-09-28
Use SB 225002 to test CXCR2-dependent neutrophil migration with a receptor-selective pharmacological control and a workflow built around dose, vehicle, and chemokine-response validation. A recent oral cancer study highlights why IL-8 biology needs receptor-specific interpretation: its reported tumor-growth mechanism centers on CXCR1, not CXCR2.
CCK-8 Opposes Electroacupuncture Analgesia
2026-09-27
A 1986 rat study found that central CCK-8 dose-dependently reduced electroacupuncture (EA) analgesia and that neutralizing endogenous CCK-8 delayed or reversed EA tolerance. The results support a model in which CCK-8 counteracts an opioid component of EA analgesia, while also highlighting the importance of injection site, peptide specificity, and stimulation history.
AMG 487: Practical CXCR3 Assay Guidance
2026-09-26
This scenario-based guide explains how to use AMG 487 (SKU B3266) to distinguish CXCR3-dependent signaling from changes in cell viability, migration, and macrophage phenotype. It connects reported potency and formulation data with practical controls, interpretation limits, and evidence from a recent inflammatory macrophage study.
PSI-7977 and Disulfidptosis: Assay Boundaries
2026-09-26
PSI-7977 is an HCV antiviral compound, not an established disulfidptosis probe. This article connects its mechanism to a practical guide for interpreting BAP1, SLC7A11, and NADPH experiments without confusing distinct biological systems.
Bestatin Enhances Endothelial Invasion in Fibrin
2026-09-25
In a fibrin-matrix model, van Hensbergen and colleagues found that bestatin increased microvascular endothelial capillary-like tube formation, despite its previously reported anti-angiogenic effects in other systems. The concentration-dependent response, together with results from CD13-directed interventions, suggests that aminopeptidases other than CD13 may contribute to endothelial invasion in this setting.